[
  {
    "ts": null,
    "headline": "Revvity Inc. stock underperforms Monday when compared to competitors",
    "summary": "Revvity Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bc7b56f6e653c35f1f66bd851dfc60a9c7413f94bbea0bffa48c183c53557258",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741022100,
      "headline": "Revvity Inc. stock underperforms Monday when compared to competitors",
      "id": 132997418,
      "image": "",
      "related": "RVTY",
      "source": "MarketWatch",
      "summary": "Revvity Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bc7b56f6e653c35f1f66bd851dfc60a9c7413f94bbea0bffa48c183c53557258"
    }
  },
  {
    "ts": null,
    "headline": "Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay",
    "summary": "WALTHAM, Mass., March 03, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum",
    "url": "https://finnhub.io/api/news?id=8c2ad6a046dba47df8c47997297198c4e69d5f836d8cd686f99698ce8199e8f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741006800,
      "headline": "Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay",
      "id": 133192980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., March 03, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum",
      "url": "https://finnhub.io/api/news?id=8c2ad6a046dba47df8c47997297198c4e69d5f836d8cd686f99698ce8199e8f7"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst performers in the research tools & consumables industry.",
    "url": "https://finnhub.io/api/news?id=b75e7e3f396592227b77872d6c744ca2019c509ec6c1838447054f9d42b47ba4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740992589,
      "headline": "Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks",
      "id": 133184867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst performers in the research tools & consumables industry.",
      "url": "https://finnhub.io/api/news?id=b75e7e3f396592227b77872d6c744ca2019c509ec6c1838447054f9d42b47ba4"
    }
  }
]